Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
Completed · Phase 3 · NCT05861427
Conditions: Migraine
At a glance
- Research payments reported, 2025
- $19,350
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 524
About the trial
- Sponsor
- AbbVie
- Tested
- Atogepant (drug), Placebo for Atogepant (drug)
- Dates
- Started 2023-07-12; completion 2025-03-01
- Results posted
- Yes
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. This study will assess how safe and effective three different doses of atogepant is compared to placebo in adult Japanese participants. Change in migraine symptoms will be assessed. Atogepant (Qulipta) is an approved drug to treat adults with episodic migraine in the United States. Participants are randomly assigned to one of the 4 treatment groups called Arms to receive atogepant or matching placebo. There is 1 in a 4 chance for the participant to receive placebo. This is double-blin…
From ClinicalTrials.gov, last updated 2026-06-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $19,350 in research payments for this study in 2025 (6 payments).
Products named: Qulipta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $19,350
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.